Effect of pilocarpine during radiation therapy: Results of RTOG 97-09, a phase III randomized study in head and neck cancer patients

Journal of Supportive Oncology

Volumn 4, Issue 5, 2006, Pages 252-258

  Scarantino, Charles W ^{a,b,c,d,e,f,g,h,i,j}   LeVeque, Francis ^{a,b,c,d,e,f,g,h,i,j}   Swann, R Suzanne ^{a,b,c,d,e,f,g,h,i,j}   White, Robert ^{a,b,c,d,e,f,g,h,i,j}   Schulsinger, Alan ^{a,b,c,d,e,f,g,h,i,j}   Hodson, D Ian ^{a,b,c,d,e,f,g,h,i,j}   Meredith, Ruby ^{a,b,c,d,e,f,g,h,i,j}   Foote, Robert ^{a,b,c,d,e,f,g,h,i,j}   Brachman, David ^{a,b,c,d,e,f,g,h,i,j}   Lee, Nancy ^{a,b,c,d,e,f,g,h,i,j}  

^a Rex Cancer Center   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c RADIATION THERAPY ONCOLOGY GROUP   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h Mayo Clinic   (United States)

ⁱ BARROW NEUROLOGICAL INSTITUTE   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PILOCARPINE; PLACEBO;

ADULT; ARTICLE; ASTHENIA; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FLUSHING; HEAD AND NECK CANCER; HUMAN; LACRIMATION DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; OROPHARYNX CARCINOMA; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINITIS; SALIVA ANALYSIS; SALIVARY GLAND; SALIVATION; SKIN DISEASE; SWEAT GLAND DISEASE; TREATMENT OUTCOME; TREMOR; URINARY DYSFUNCTION; URINARY FREQUENCY; XEROSTOMIA;

FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUSCARINIC AGONISTS; PILOCARPINE; QUALITY OF LIFE; RADIATION INJURIES; SALIVATION; STOMATITIS; XEROSTOMIA;

EID: 33646792561     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Greenspan JS, Melamed MR, Pearse AGE. Early histochemical changes in irradiated salivary glands and lymph nodes of the rat. J Pathol Bacteriol 1964:88:439-453.
2. Stephens LC, King GK, Peters LJ, et al. Radiosensitivity of serous cells in rhesus monkey submandibular glands. Am J Pathol 1986:124:479-487.
3. Cheng VST, Downs J, Herbert D, Aramany M. The function of the parotid gland following radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys 1981:7:253-258.
4. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998:34:39-43.
5. Pajak TF, Laramore GE, Marcial VA, et al. Elapsed treatment days - a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys 1991:20:13-30.
6. National Institutes of Health. Consensus Development Conference Statement in Oral Complication of Cancer Therapies, Diagnosis, Prevention and Treatment. Bethesda, MD: April 17-19, 1989:7:1-12.
7. Brown LR, Dreizen S, Daly TE, et al. Interrelations of oral microorganisms, immunoglobulins, and dental caries following radiotherapy. J Dent Res 1978:57:882-893.
8. Chencharick JD, Mossman KL. Nutritional consequences of the radiotherapy of head and neck cancer. Cancer 1983:51:811-815.
9. Greenspan D, Daniels TE. Effectiveness of pilocarpine in post-radiation xerostomia. Cancer 1987:59:1123-1125.
10. Wolff A, Atkinson JC, Macynski AA, et al. Pretherapy interventions to modify salivary dysfunction. NCI Monogr 1990:9:87-90.
11. Kim KH, Kim JY, Sung MW et al. The effect of pilocarpine and atropine administration on radiation-induced injury of rat submandibular glands. Acta Otolaryngol 1991:111:967-973.
12. Johnson JT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993:329:390-395.
13. LeVeque FG, Montgomery MM, Potter D, et al. A multicenter, randomized, double blind, placebo-controlled, dose titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 1993:11:1124-1131.
14. Rieke JW, Heferman MD, Johnson JT, et al. Oral pilocarpine for radiation induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. Int J Radiat Oncol Biol Phys 1995:31:661-669.
15. Horiot J, Lipinski F, Schraub S, et al. Post radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiother Oncol 2000:55:233-239.
16. LeVeque FG, Fontanesi J, Klein BJ, et al. Pilot study to determine if oral pilocarpine given concurrently with head and neck irradiation can decrease the incidence and severity of salivary gland dysfunction. Presented at the 32nd Annual Meeting of the American Society of Clinical Oncology. May 18-21, 1996. Philadelphia, Pa. Abstract 1665.
17. Zimmerman RP, Mark RJ, Jhuillard GF. Timing of pilocarpine treatment during head and neck radiotherapy: concomitant administration reduces xerostomia better than post irradiation pilocarpine. Int J Radiat Oncol Biol Phys 1996;36(suppl):236.
18. Travis EL. The oxygen dependence of protection by aminothiols: implications for normal tissues and solid tumors. Int J Radiat Oncol Biol Phys 1984:10:1495-1501.
19. Brizel DM, Wasserman T, Henke M, et al. Phase III randomized trial of amifostine as radioprotector in head and neck cancer. J Clin Oncol 2000:18:3339-3345.
20. Rudat V, Meyer J, Momm F, et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. Int J Radiat Oncol Biol Phys 2000:48:1339-1343.
21. Epstein JB, Stevenson-Moore P, Jackson S, et al. Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Int J Radiat Oncol Biol Phys 1989:16:1571-1575.
22. Rosso M, Blasi G, Gherlone E, et al. Effect of granulocyte-macrophage colony stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemoradiotherapy. J Chemother 1997:9:382-385.
23. Dunphy F, Kim G, Dunleavy T, et al. Granulocyte monocyte colony stimulating factor (GM-CFS) ameliorates radiation mucositis. Presented at the 39th Annual Meeting of the American Society Hematology. December 5-9, 1997. San Diego, Calif. Abstract 3552.
24. Makkonen T, Minn H, Jekunen A, et al. Granulocyte macrophage colony-stimulating factor (GM-CSF) and sucralfate in prevention of radiation induced mucositis: a prospective randomized study. Int J Radiat Oncol Biol Phys 2000:46:525-534.
25. Hassan SJ, Weymuller EA Jr. Assessment of quality of life in head and neck cancer patients. Head Neck 1993:15:485-496.
26. Reike JW, Hafermann MD, Johnson JT, et al. Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. Int J Radiat Oncol Biol Phys 1997:31:661-669.
27. Wasserman TH, Brizel DM, Henke M, et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 2005:63:985-990.
28. Jha N, Seikaly H, McGaw T, et al. Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiother Oncol 2003:66:283-289.
29. Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid-sparing irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 2001:50:695-704.
30. Eisbruch A, Kim HM, Ten Haken R, et al. Dose, volume and function relationships in parotid glands following conformal and intensity modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 1999:45:577-587.
31. Fisher J, Scott C, Scarantino CW, et al. Phase III quality of life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and -neck cancer - RTOG 97-09. Int J Radiat Oncol Biol Phys 2003:56:832-836.
32. Warde P, O'Sullivan B, Aslanidis J, et al. A phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2002:54:9-13.
33. Fox PC, Busch KA, Baum BJ. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc 1987:115:581-584.
34. Liem IH, Olmos RA, Balm AJM, et al. Evidence of early and persistent impairment of salivary gland excretion after irradiation of head and neck tumours. Eur J Nucl Med 1996:23:1485-1490.
35. Clark SJ, Davies ID, Schnell FM, et al. Recombinant human keratinocyte growth factor prevents chemotherapy-induced mucositis in patients with advanced colorectal cancer: a randomized phase II trial. J Clin Oncol 2001:20:383a. Abstract 1529.
36. Spielberger RT, Stiff PJ, Emmanouilides C, et al. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-pbpc) after radiation-based conditioning - results of a phase II trial. J Clin Oncol 2001:20:7a. Abstract 25.